Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
GoldInxs Mining Corp. Files Final Prospectus in Connection with Initial Public OfferingThe final prospectus is available through SEDAR+
America Needs Antimony, and This Nevada Explorer Just Defined One of the Largest Domestic Resources of It
NEVGOLD ANNOUNCES MINERAL RESOURCE: ANTIMONY OF 29,600 TONNES MEASURED & INDICATED AND 48,100 TONNES INFERRED ; 100% OXIDE GOLD OF 181,400 OZS MEASURED & INDICATED AND 1,203,500 OZS INFERRED; STRATEGIC U.S. ANTIMONY RESOURCE
SAGA Metals Reports Assays from R-0047 to R-0049 with Intercepts Including 53.72% Fe2O3, 7.32% TiO2, 0.431% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
